FDA approves Siliq (brodalumab) for psoriasis

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

FDA approved Siliq (brodalumab), as an injection for the treatment of adults with moderate-to-severe plaque psoriasis. Siliq is intended for patients receiving systemic therapy or phototherapy and have failed to respond other systemic therapies.

Psoriasis is an autoimmune disorder which more commonly occurs in patients with a family history of the disease and most often in people 15 to 35 years of age. Psoriasis cause patches of red skin and flakes. Plaque psoriasis is most common form of psoriasis causing thick, red flaky skin, silver-white scales.

Brodalumab inhibits the inflammatory response responsible for the development of plaque psoriasis by binding to a protein which cause inflammation.

The safety and efficacy of Siliq was established in 3 randomized, placebo-controlled clinical trials of 4,373 adult participants with moderate-to-severe plaque psoriasis who received systemic therapy or phototherapy. Patients treated with Siliq had clear or almost clear skin compared to placebo as evaluated by scoring of the e...

Recommended for you

  • FDA Drug Updates
  • 1 comment

Approval of Xermelo (telotristat ethyl) for carcinoid syndrome diarrhea

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Edex (alprostadil injection) 10 mcg by Endo Pharmaceuticals - Lack of sterility assurance

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of unexpired sterile injectable labelled “Latex Free” by Advanced Pharma as it may contain synthetic/natural latex

Read more
  • FDA Drug Updates
  • 1 comment

FDA approves Siliq (brodalumab) for psoriasis

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Parsabiv (etelcalcetide) for hyperparathyroidism in dialysis patients

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of XtraHRD Natural Male Enhancement Capsules by Organic Herbal Supply - Contains undeclared drug ingredients

Read more
  • FDA Drug Updates
  • 1 comment

FDA approval of Emflaza (deflazacort) for duchenne muscular dystrophy

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Human chorionic gonadotropin freeze dried vials by Synergy Rx – Lack of sterility assurance

Read more
  • FDA Drug Updates
  • 1 comment

Approval of Trulance (plecanatide) for chronic idiopathic constipation

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Ibuprofen lysine injection, 20 mg /2 mL by Exela Pharma Sciences – Presence of particulate matter

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Well Balance Xanthium & Siler Combo dietary supplement by Kingsway - Contains banned ephedra alkaloids

Read more
  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Alaris Syringe Pump Module by CareFusion – Faulty sensor may generate false alarm

Read more
  • FDA Drug Updates
  • 1 comment

First drug approved for treatment of spinal muscular atrophy

Read more
  • MedWatch Drug Updates
  • 1 comment

Chlorhexidine gluconate - Rare but serious allergic reactions have been reported

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Rubraca (rucaparib) for BRCA+ advanced ovarian cancer

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Eucrisa (crisaborole) for atopic dermatitis

Read more
  • MedWatch Drug Updates
  • no comment

Class I Recall of Halo One Thin-Walled Guiding Sheath by Bard Peripheral Vascular

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of vancomycin hydrochloride for Injection, USP by Hospira - Presence of particulate matter in vial

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Soliqua 100/33 (insulin glargine and lixisenatide) for type II diabetes

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Xultophy 100/3.6 (insulin degludec and liraglutide injection)

Read more
  • MedWatch Drug Updates
  • 1 comment

Class I Recall of FindrWIRZ Guidewire System by SentreHeart – Possible separation of polytetrafluoroethylene coating

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Intrarosa (prasterone) for dyspareunia

Read more
  • FDA Drug Updates
  • 1 comment

FDA approves Tecentriq (atezolizumab) for treatment of urothelial carcinoma

Read more
  • MedWatch Drug Updates
  • 1 comment

ED-3490TK video duodenoscope by Pentax – Recommendations update to prevent patient infection

Read more
  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Dialog+ Hemodialysis System by B. Braun Medical due to defective conductivity sensors

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Nuplazid (pimavanserin) for Parkinson’s disease psychosis

Read more
  • MedWatch Drug Updates
  • 1 comment

Fujifilm Medical Systems has removed certain older duodenoscope models

Read more
  • MedWatch Drug Updates
  • 1 comment

Class I Recall of Ventricular assist device pumps by HeartWare – Loose connection may cause alarm failure

Read more
  • MedWatch Drug Updates
  • 1 comment

TAH-t Companion 2 and Freedom Driver System by SynCardia Systems – Risk of mortality and neurological adverse

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA urges not to use PNC products for cancer treatment due to microbial contamination

Read more